-10:
71.2
71.3
71.4
.72 ( , - , )
.72.0
.72.1
.72.2
.72.3 , ,
(SOGC, 2009)
(70%) | ||
(≥5 ) | ||
- | ||
() | ||
(20%) | ||
(10%) | , , | |
(1%) | ( , ) | |
: ; ; ( , , , ) | / , , HELLP- | |
(RCOG, 2009)
.
− (OR- 13,0 (7,61-12,9)
− (OR- 12,0 (7,17-23,0)
− (OR- 5,0 (3,0-6,6)
− / (OR- 4,0)
:
− (OR- 3,0)
− (OR- 2,0 (1,48-2,12)
|
|
− ( 35) (OR- 2,0 (1,24-2,17)
− ( 90 /) (OR- 2,0 (1,63-3,15)
, :
− (OR- 4,0 (3,28-3,95)
− (OR- 2,0 (2,18-2,80)
− (OR- 2,0 (1,67-2,95)
− (OR- 5,0 (3,35-7,87)
− (OR- 5,0)
− 12 (OR- 2,0)
− (OR- 2,0 (1,56-2,07)
− 4 (OR- 2,0 (1,38-2,60)
− (OR- 2,0)
− 40 (OR- 1,4 (1,16-1,74)
:
− .
− .
−
− :
− 5-10 / (+ 10 /). 20-30 500 0,9% 150-200 /.
− 0,25 /, 0,125 /. , , , , . 5 .
− , (15-methyl PGF2 alpha) / / 0,25 . 15 8 . : , , , , .
, , - , , .
− 800-1000 per rectum. PGF2 alpha.
:
- ( - 15 /
) 1,0 / . ( - 15 / .. 1,0 / ).
− 10 / 1,0 /.